Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY AND DETERMINE THE MAXIMUM TOLERATED DOSE OF PF-05230907 IN SUBJECTS WITH INTRACEREBRAL HEMORRHAGE (ICH)

NCT02687191 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02687191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02687191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY AND DETERMINE THE MAXIMUM TOLERATED DOSE OF PF-05230907 IN SUBJECTS WITH INTRACEREBRAL HEMORRHAGE (ICH)
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
November 30, 2016
Completion date
January 31, 2018
Enrollment
21 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

intracerebral hemorrhage